Michael H. Mulroy
CIK 1509725 · President and CEO · last filed 2026-07-02
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
QCOR price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ANAHEIM, CA 92807
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| LCTX | Director | 298,555 | $1.02 | $306.0K | $32.4K | 10 | 2026-07-02 |
| Serina Therapeutics, Inc. (AGE) Delisted | Director | — | $11.10 | — | $0 | 1 | 2019-03-13 |
| Asterias Biotherapeutics, Inc. (AST) Delisted | President and CEO | 350,210 | — | — | $54.9K | 13 | 2019-03-05 |
| Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Director | 32,550 | — | — | $0 | 4 | 2018-07-03 |
| Asterias Biotherapeutics, Inc. (AST.WS) Delisted | President and CEO | 1,537 | — | — | $5.0K | 2 | 2017-09-27 |
| QUESTCOR PHARMACEUTICALS INC (QCOR) Delisted | See Remarks | 65,714 | — | — | -$2.44M | 11 | 2014-08-13 |
| BTX | Director | 35 | $8.63 | $302 | $0 | 3 | 2013-10-10 |
Recent Filings · Page 3 of 5
47 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-03-28 | Asterias Biotherapeutics, Inc. (AST) Delisted | Buy (P) | +2,839 | $5.0K | EDGAR |
| 2018-03-19 | Asterias Biotherapeutics, Inc. (AST) Delisted | Mixed | +66,514 | -$55.3K | EDGAR |
| 2018-02-28 | Asterias Biotherapeutics, Inc. (AST) Delisted | Buy (P) | +2,255 | $5.0K | EDGAR |
| 2018-01-26 | Asterias Biotherapeutics, Inc. (AST) Delisted | Buy (P) | +2,134 | $5.0K | EDGAR |
| 2017-12-28 | Asterias Biotherapeutics, Inc. (AST) Delisted | Buy (P) | +2,247 | $5.0K | EDGAR |
| 2017-11-29 | Asterias Biotherapeutics, Inc. (AST) Delisted | Buy (P) | +2,076 | $5.0K | EDGAR |
| 2017-10-27 | Asterias Biotherapeutics, Inc. (AST) Delisted | Buy (P) | +1,939 | $4.9K | EDGAR |
| 2017-09-27 | Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Buy (P) | +1,537 | $5.0K | EDGAR |
| 2017-07-05 | Lineage Cell Therapeutics, Inc. (BTX.WS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-28 | Asterias Biotherapeutics, Inc. (AST.WS) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.